Orion Corporation announced that darolutamide has received approval from the European Commission for use in patients with metastatic hormone-sensitive prostate cancer. The approval is based on positive results from the Phase III ARANOTE trial, showing a 46% reduction in risk of progression or death compared to placebo. Darolutamide is already approved in over 85 countries for various prostate cancer treatments. Prostate cancer is a significant health concern globally, with millions of new cases diagnosed each year. Darolutamide, an oral androgen receptor inhibitor, offers a promising treatment option for patients with metastatic hormone-sensitive prostate cancer.

Read more at GlobeNewswire: Darolutamide receives EU approval in third indication for